Survival rates of familial and sporadic prostate cancer patients.

AIM - To compare cancer-specific survival rates for familial and sporadic prostate cancer patients.

METHODS - Gleason score and age at diagnosis of familial group and sporadic group were compared by χ(2) and t-test. Cancer-specific survival rates were analyzed by the Kaplan - Meier method and compared by log-rank test. Statistically significant level was set at p < 0.05.

RESULTS - Among 1175 prostate cancer patients, familial group consisted of 215 (18.3%) patients, the sporadic group consisted of 960 (81.7%) patients. The familial group patient's mean age at diagnosis (58.9 years old, 95% confidence interval (CI) 57.8-60.1) was significantly younger than that of sporadic group patients (67.2 years old, 95% CI 66.7-67.6) (p < 0.0001). Comparing Gleason score between familial group and sporadic group revealed no statistically significant difference. The analysis showed that 92% (95% CI 0.88-0.97) of familial group patients had a 10-year cancer-specific survival rates, which was a significantly better outcome than that of sporadic group with 69% (95% CI 0.60-0.78) 10-year cancer-specific survival rates (p = 0.0237).

CONCLUSIONS - The study data demonstrate statistically significant difference between familial group and sporadic group concerning age and cancer-specific survival rates, but not Gleason score.

Exp Oncol. 2015 Jun;37(2):154-5.

Plonis J1, Nakazawa-Miklasevica M1, Malevskis A2, Vaganovs P1, Pildava S3, Vjaters E1, Gardovskis J1, Miklasevics E1.

1 Institute of Oncology, Riga Stradins University, Riga LV-1007, Latvia.
2 Center of Urology, Pauls Stradins University Hospital, Riga LV-1007, Latvia.
3 Center for Disease Prevention and Control, Riga LV-1007, Latvia.